Document Detail


Prospective comparison of breast pain in patients participating in a randomized trial of breast-conserving surgery and tamoxifen with or without radiotherapy.
MedLine Citation:
PMID:  12504048     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To determine whether breast pain affects quality of life (QOL) after breast-conserving surgery and tamoxifen (TAM) with or without adjuvant breast radiotherapy (RT). METHODS AND MATERIALS: A randomized clinical trial was carried out at the Princess Margaret Hospital between 1992 and 2000 to evaluate the need for breast RT in addition to TAM in women >or=50 years treated with breast-conserving surgery for T1-T2N0 breast cancer. A companion study to assess breast pain was carried out during the last 2 years of the randomized clinical trial. The short-form McGill Pain Questionnaire (SF-MPQ), the European Organization for Research and Treatment of Cancer (EORTC) QOL (QLQ-C30) and EORTC breast cancer module (QLQ-BR23) questionnaires were completed by patients within 1 week of randomization in the randomized clinical trial (baseline) and at 3, 6, and 12 months. RESULTS: Eighty-six patients participated in the breast pain study; 41 received RT plus TAM and 45 received TAM alone. The median age was 70 years (range 51-80). The baseline pain and QOL scores were similar for the two groups. No significant difference was found between the two groups for each scale of the QLQ-C30 and QLQ-BR23 questionnaires at 3, 6, or 12 months (p >0.100), except that at 12 months, the score for role function (QLQ-C30) was higher in the RT plus TAM group than in the RT-only group (p = 0.02). At 3 months, the difference between the mean scores for the SF-MPQ was 0.553 (p = 0.47). At 12 months, the pain scores had decreased in both groups; the difference was 0.199 (p = 0.71). The number of breast operations or surgical complications did not correlate with breast pain in either group. Acute RT toxicity scores did not correlate with breast pain or QOL scores at 12 months. CONCLUSION: These results suggest that breast RT does not significantly contribute to breast pain or adversely impact the QOL up to 12 months after treatment in postmenopausal patients with node-negative breast cancer who take TAM.
Authors:
Gamal Rayan; Laura A Dawson; Andrea Bezjak; Anthea Lau; Anthony W Fyles; Qi Long Yi; Pat Merante; Katherine A Vallis
Related Documents :
18722938 - Outcomes of multiple wire localization for larger breast cancers: when can mastectomy b...
19956768 - Behavior of buff-breasted sandpipers (tryngites subruficollis) during migratory stopove...
18502528 - Local relapse rates are falling after breast conserving surgery and systemic therapy fo...
19638208 - Tumor aromatase expression as a prognostic factor for local control in young breast can...
21535078 - Different perforin expression in peripheral blood and prostate tissue in patients with ...
17986798 - Significance and problems of histopathological examination and utility of real-time rev...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  55     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2002-12-30     Completed Date:  2003-01-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  154-61     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Princess Margaret Hospital/University Health Network and University of Toronto, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Breast / physiopathology*
Breast Neoplasms / physiopathology,  psychology,  therapy*
Combined Modality Therapy
Female
Humans
Middle Aged
Pain / etiology*
Postoperative Complications / etiology
Prospective Studies
Quality of Life
Radiotherapy / adverse effects
Tamoxifen / therapeutic use*
Chemical
Reg. No./Substance:
10540-29-1/Tamoxifen
Comments/Corrections
Comment In:
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1508-9; author reply 1509   [PMID:  12873700 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in p...
Next Document:  Clinical results of retreatment of vertebral bone metastases by stereotactic conformal radiotherapy ...